|
1
|
Pan SY, Litscher G, Gao SH, Zhou SF, Yu
ZL, Chen HQ, Zhang SF, Tang MK, Sun JN and Ko KM: Historical
perspective of traditional indigenous medical practices: The
current renaissance and conservation of herbal resources. Evid
Based Complement Alternat Med. 2014:5253402014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
World Health Organization (WHO), . WHO
Global Report on Traditional and Complementary Medicine 2019. WHO;
Geneva: 2019
|
|
3
|
Ismail SF, Azmi IMAG, Daud M, Jalil JA and
Safuan S: Regulatory control of herbal and traditional medicines in
malaysia: Issues and concerns. Int J Business Society. 21:192–204.
2020.
|
|
4
|
Shehzad A, Islam SU, AL-Suhaimi EA and Lee
YS: Pleiotropic effects of bioactive phytochemicals (Polyphenols
and Terpenes). Functional Foods, Nutraceuticals and Natural
Products. DEStech Publications Inc.; 2018
|
|
5
|
Nishino H, Tokuda H, Satomi Y, Masuda M,
Onozuka M, Yamaguchi S, Takayasu J, Tsuruta J, Takemura M, Ii T, et
al: Cancer chemoprevention by phytochemicals and their related
compounds. Asian Pac J Cancer Prev. 1:49–55. 2000.PubMed/NCBI
|
|
6
|
Amin ARMR, Kucuk O, Khuri FR and Shin DM:
Perspectives for cancer prevention with natural compounds. J Clin
Oncol. 27:2712–2725. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nisar B, Sultan A and Rubab SL: Comparison
of medicinally important natural products versus synthetic drugs-a
short commentary. Nat Prod Chem Res. 6:22018. View Article : Google Scholar
|
|
8
|
Gao Q, Feng J, Liu W, Wen C, Wu Y, Liao Q,
Zou L, Sui X, Xie T, Zhang J and Hu Y: Opportunities and challenges
for co-delivery nanomedicines based on combination of
phytochemicals with chemotherapeutic drugs in cancer treatment. Adv
Drug Deliv Rev. 188:1144452022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bode AM and Dong Z: Toxic phytochemicals
and their potential risks for human cancer. Cancer Prev Res
(Phila). 8:1–8. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kudva AK, Rao S, Rao P, Periera R,
Bhandari G, Mathew JM, Ashwini K, Pais M, Swamy MK and Baliga M:
Piper betle Linn, in cancer: Past, present, and future. Anticancer
plants: Properties and Application. Vol 1. Springer; Singapore: pp.
327–347. 2018
|
|
11
|
Guha P: Betel leaf: The neglected green
gold of india. J Hum Ecol. 19:87–93. 2006. View Article : Google Scholar
|
|
12
|
Amonkar AJ, Nagabhushan M, D'Souza AV and
Bhide SV: Hydroxychavicol: A new phenolic antimutagen from betel
leaf. Food Chem Toxicol. 24:1321–1324. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Amonkar AJ, Padma PR and Bhide SV:
Protective effect of hydroxychavicol, a phenolic component of betel
leaf, against the tobacco-specific carcinogens. Mutat Res.
210:249–253. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chaveerach A, Mokkamul P, Sudmoon R and
Tanee T: Ethnobotany of the Genus Piper (Piperaceae) in
Thailand. Ethnobotany Research Applications. 4:2232006. View Article : Google Scholar
|
|
15
|
Shah GA, Shah TI, Telang S, Science G,
Nehru J and Hospital C: Anti-proliferative efficacy of piper betle
leaf extracts against B16F10 melanoma in an in vivo. World J Pharm
Pharm Sci. 5:835–843. 2016.
|
|
16
|
Haslan H, Suhaimi FH, Thent ZC and Das S:
The underlying mechanism of action for various medicinal properties
of Piper betle (betel). Clin Ter. 166:208–214. 2015.PubMed/NCBI
|
|
17
|
Agarwal T, Singh R, Shukla AD, Waris I and
Gujrati A: Comparative analysis of antibacterial activity of four
Piper betel varieties. Adv Appl Sci Res. 3:698–705. 2012.
|
|
18
|
Chakraborty D and Shah B: Antimicrobial,
anti-oxidative and anti-hemolytic activity of Piper betel leaf
extracts. Int J Pharm Pharm Sci. 3:192–199. 2011.
|
|
19
|
Kumar N, Misra P, Dube A, Bhattacharya S,
Dikshit M and Ranade S: Piper betle Linn. A maligned pan-asiatic
plant with an array of pharmacological activities and prospects for
drug discovery. Curr Sci. 99:922–932. 2010.
|
|
20
|
Punuri JB, Sharma P, Sibyala S, Tamuli R
and Bora U: Piper betle-mediated green synthesis of biocompatible
gold nanoparticles. Int Nano Lett. 2:182012. View Article : Google Scholar
|
|
21
|
Sharma S, Khan IA, Ali I, Ali F, Kumar M,
Kumar A, Johri RK, Abdullah ST, Bani S, Pandey A, et al: Evaluation
of the antimicrobial, antioxidant, and anti-inflammatory activities
of hydroxychavicol for its potential use as an oral care agent.
Antimicrob Agents Chemother. 53:216–222. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Madhumita M, Guha P and Nag A: Bio-actives
of betel leaf (Piper betle L.): A comprehensive review on
extraction, isolation, characterization, and biological activity.
Phytother Res. 34:2609–2627. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Das S, Parida R, Sandeep IS, Nayak S and
Mohanty S: Biotechnological intervention in betelvine (Piper betle
L.): A review on recent advances and future prospects. Asian Pac J
Trop Med. 9:938–946. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rahman AA, Mokhtar NM, Harun R, Jamal R
and Ngah WZ: Transcriptome analysis reveals the molecular
mechanisms of combined gamma-tocotrienol and hydroxychavicol in
preventing the proliferation of 1321N1, SW1783, and LN18 glioma
cancer cells. J Physiol Biochem. 75:499–517. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chakraborty JB, Mahato SK, Joshi K, Shinde
V, Rakshit S, Biswas N, Mukherjee IC, Mandal L, Ganguly D,
Chowdhury AA, et al: Hydroxychavicol, a Piper betle leaf component,
induces apoptosis of CML cells through mitochondrial reactive
oxygen species-dependent JNK and endothelial nitric oxide synthase
activation and overrides imatinib resistance. Cancer Sci.
103:88–99. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Prabhu MS, Platel K, Saraswathi G and
Srinivasan K: Effect of orally administered betel leaf (Piper betle
Linn.) on digestive enzymes of pancreas and intestinal mucosa and
on bile production in rats. Indian J Exp Biol. 33:752–756.
1995.PubMed/NCBI
|
|
27
|
Majumdar AG and Subramanian M:
Hydroxychavicol from Piper betle induces apoptosis, cell cycle
arrest, and inhibits epithelial-mesenchymal transition in
pancreatic cancer cells. Biochem Pharmacol. 166:274–291. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee-Chen SF, Chen CL, Ho LY, Hsu PC, Chang
JT, Sun CM, Chi CW and Liu TY: Role of oxidative DNA damage in
hydroxychavicol-induced genotoxicity. Mutagenesis. 11:519–523.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tang DW, Lin SC, Chang KW, Chi CW, Chang
CS and Liu TY: Elevated expression of cyclooxygenase (COX)-2 in
oral squamous cell carcinoma-evidence for COX-2 induction by areca
quid ingredients in oral keratinocytes. J Oral Pathol Med.
32:522–529. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chang MC, Uang BJ, Tsai CY, Wu HL, Lin BR,
Lee CS, Chen YJ, Chang CH, Tsai YL, Kao CJ and Jeng JH:
Hydroxychavicol, a novel betel leaf component, inhibits platelet
aggregation by suppression of cyclooxygenase, thromboxane
production and calcium mobilization. Br J Pharmacol. 152:73–82.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chang MC, Uang BJ, Wu HL, Lee JJ, Hahn LJ
and Jeng JH: Inducing the cell cycle arrest and apoptosis of oral
KB carcinoma cells by hydroxychavicol: Roles of glutathione and
reactive oxygen species. Br J Pharmacol. 135:619–130. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Arksey H and O'Malley L: Scoping studies:
Towards a methodological framework. International J Social Research
Methodology: Theory and Practice. 8:19–32. 2005. View Article : Google Scholar
|
|
33
|
Liberati A, Altman DG, Tetzlaff J, Mulrow
C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J
and Moher D: The PRISMA statement for reporting systematic reviews
and meta-analyses of studies that evaluate health care
interventions: Explanation and elaboration. J Clin Epidemiol.
62:e1–e34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Thi Truc Nguyen L, Thi Nguyen T, Ngoc
Nguyen H and Thi Phuong Bui Q: Simultaneous determination of active
compounds in Piper betle Linn. leaf extract and effect of
extracting solvents on bioactivity. Eng Reps. 2:e122462020.
|
|
35
|
Ali A, Lim XY, Chong CH, Mah SH and Chua
BL: Optimization of ultrasound-assisted extraction of natural
antioxidants from Piper betle using response surface methodology.
LWT. 89:681–688. 2018. View Article : Google Scholar
|
|
36
|
Pin KY, Chuah AL, Rashih AA, Mazura MP,
Fadzureena J, Vimala S and Rasadah MA: Antioxidant and
anti-inflammatory activities of extracts of betel leaves (Piper
betle) from solvents with different polarities. J Tropical Forest
Sci. 22:448–455. 2010.
|
|
37
|
Zamakshshari N, Ahmed IA and Nasharuddin
MNA: Effect of extraction procedure on the yield and biological
activities of hydroxychavicol from Piper betle L. leaves. J Appl
Res Med Aromat Plants. 24:1003202021.
|
|
38
|
Ali A, Chong CH, Mah SH, Abdullah LC,
Choong TSY and Chua BL: Impact of storage conditions on the
stability of predominant phenolic constituents and antioxidant
activity of dried piper betle extracts. Molecules. 23:4842018.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gundala SR and Aneja R: Piper betel leaf:
A reservoir of potential xenohormetic nutraceuticals with
cancer-fighting properties. Cancer Prev Res (Phila). 7:477–486.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mira L, Fernandez MT, Santos M, Rocha R,
Florêncio MH and Jennings KR: Interactions of flavonoids with iron
and copper ions: A mechanism for their antioxidant activity. Free
Radic Res. 36:1199–1208. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Halliwell B: Biochemistry of oxidative
stress. Biochem Soc Trans. 35:1147–1150. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen X, Song M, Zhang B and Zhang Y:
Reactive oxygen species regulate T cell immune response in the
tumor microenvironment. Oxid Med Cell Longev. 2016:15809672016.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Juan CA, de la Lastra JM, Plou FJ and
Pérez-Lebeña E: The chemistry of reactive oxygen species (ROS)
revisited: Outlining their role in biological macromolecules (DNA,
Lipids and Proteins) and induced pathologies. Int J Mol Sci.
22:46422021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hayes JD, Dinkova-Kostova AT and Tew KD:
Oxidative stress in cancer. Cancer Cell. 38:167–197. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kim SJ, Kim HS and Seo YR: Understanding
of ROS-inducing strategy in anticancer therapy. Oxid Med Cell
Longev. 2019:53816922019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ureshino H, Shindo T and Kimura S: Role of
cancer immunology in chronic myelogenous leukemia. Leuk Res.
88:1062732020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hochhaus A, Larson RA, Guilhot F, Radich
JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F,
Fujihara S, et al: Long-term outcomes of imatinib treatment for
chronic myeloid leukemia. N Engl J Med. 376:917–927. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Paul T, Banerjee A, Reddy SVB, Mahato SK
and Biswas N: Hydroxychavicol sensitizes imatinib-resistant chronic
myelogenous leukemia cells to TRAIL-induced apoptosis by
ROS-mediated IAP downregulation. Anticancer Drugs. 30:167–178.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chowdhury AA, Chaudhuri J, Biswas N, Manna
A, Chatterjee S, Mahato SK, Chaudhuri U, Jaisankar P and
Bandyopadhyay S: Synergistic apoptosis of CML cells by buthionine
sulfoximine and hydroxychavicol correlates with activation of AIF
and GSH-ROS-JNK-ERK-iNOS pathway. PLoS One. 8:e736722013.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chaudhuri J, Chowdhury AA, Biswas N, Manna
A, Chatterjee S, Mukherjee T, Chaudhuri U, Jaisankar P and
Bandyopadhyay S: Superoxide activates mTOR-eIF4E-Bax route to
induce enhanced apoptosis in leukemic cells. Apoptosis. 19:135–148.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
World Health Organization (WHO), .
GLOBOCAN 2020. WHO; Geneva: 2020
|
|
52
|
Perou CM, Sørile T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Cazzaniga M and Bonanni B: Breast cancer
chemoprevention: Old and new approaches. J Biomed Biotechnol.
2012:985620S2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Neven P, Jongen L, Lintermans A, Van Asten
K, Blomme C, Lambrechts D, Poppe A, Wildiers H, Dieudonné AS,
Brouckaert O, et al: Tamoxifen metabolism and efficacy in breast
cancer: A prospective multicenter trial. Clin Cancer Res.
24:2312–2318. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Waters EA, McNeel TS, Stevens WM and
Freedman AN: Use of tamoxifen and raloxifene for breast cancer
chemoprevention in 2010. Breast Cancer Res Treat. 134:875–880.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Chumsri S, Howes T, Bao T, Sabnis G and
Brodie A: Aromatase, aromatase inhibitors, and breast cancer. J
Steroid Mol Biol. 125:13–22. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Tong CWS, Wu M, Cho WCS and To KKW: Recent
advances in the treatment of breast cancer. Front Oncol. 8:2272018.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Kreutzfeldt J, Rozeboom B, Dey N and De P:
The trastuzumab era: Current and upcoming targeted HER2+ breast
cancer therapies. Am J Cancer Res. 10:1045–1067. 2020.PubMed/NCBI
|
|
59
|
Sinha D, Biswas J, Sung B, Aggarwal BB and
Bishayee A: Chemopreventive and chemotherapeutic potential of
curcumin in breast cancer. Curr Drug Targets. 13:1799–1819. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Hemamalini V, Velayutham DPM, Lakshmanan
L, Muthusamy K, Sivaramakrishnan S and Premkumar K: Inhibitory
potential of Hydroxychavicol on Ehrlich ascites carcinoma model and
in silico interaction on cancer targets. Nat Prod Res.
34:1591–1596. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
McGuigan A, Kelly P, Turkington RC, Jones
C, Coleman HG and McCain RS: Pancreatic cancer: A review of
clinical diagnosis, epidemiology, treatment and outcomes. World J
Gastroenterol. 24:4846–4861. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Burris HA III, Moore MJ, Andersen J, Green
MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo
AM, Tarassoff P, et al: Improvements in survival and clinical
benefit with gemcitabine as first-line therapy for patients with
advanced pancreas cancer: A randomized trial. J Clin Oncol.
15:2403–2413. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Conroy T, Hammel P, Hebbar M, Abdelghani
MB, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, et
al: FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic
cancer. N Eng J Med. 379:2395–2406. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Neuzillet C, Gaujoux S, Williet N, Bachet
JB, Bauguion L, Durand LC, Conroy T, Dahan L, Gilabert M, Huguet F,
et al: Pancreatic cancer: French clinical practice guidelines for
diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER,
SFCD, SFED, SFRO, ACHBT, AFC). Dig Liver Dis. 50:1257–1271. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Hamdy FC, Donovan JL, Lane JA, Mason M,
Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, et
al: 10-year outcomes after monitoring, surgery, or radiotherapy for
localized prostate cancer. N Eng J Med. 375:1415–1424. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Armstrong CM and Gao AC: Adaptive pathways
and emerging strategies overcoming treatment resistance in
castration resistant prostate cancer. Asian J Urol. 3:185–194.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Gundala SR, Yang C, Mukkavilli R, Paranjpe
R, Brahmbhatt M, Pannu V, Cheng A, Reid MD and Aneja R:
Hydroxychavicol, a betel leaf component, inhibits prostate cancer
through ROS-driven DNA damage and apoptosis. Toxicol Appl
Pharmacol. 280:86–96. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Kuipers EJ, Grady WM, Lieberman D,
Seufferlein T, Sung JJ, Boelens PG, van de Velde CJH and Watanabe
T: Colorectal cancer. Nat Rev Dis Primers. 1:50652015. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Yalcin-Ozkat G: Molecular modeling
strategies of cancer multidrug resistance. Drug Resist Updat.
59:1007892021. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Rajedadram A, Pin KY, Ling SK, Yan SW and
Looi ML: Hydroxychavicol, a polyphenol from Piper betle leaf
extract, induces cell cycle arrest and apoptosis in TP53-resistant
HT-29 colon cancer cells. J Zhejiang Univ Sci B. 22:112–122. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Bahadur S, Sahu AK, Baghel P and Saha S:
Current promising treatment strategy for glioblastoma multiform: A
review. Oncol Rev. 13:4172019. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Thakkar JP, Dolecek TA, Horbinski C,
Ostrom QT, Lightner DD, Barnholtz-Sloan JS and Villano JL:
Epidemiologic and molecular prognostic review of glioblastoma.
Cancer Epidemiol Biomarkers Prev. 23:1985–1996. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Koshy M, Villano JL, Dolecek TA, Howard A,
Mahmood U, Chmura SJ, Weichselbaum RR and McCarthy BJ: Improved
survival time trends for glioblastoma using the SEER 17
population-based registries. J Neurooncol. 107:207–212. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Rahman AA, Jamal AR, Harun R, Mokhtar NM
and Ngah WZ: Gamma-tocotrienol and hydroxy-chavicol synergistically
inhibits growth and induces apoptosis of human glioma cells. BMC
Complement Altern Med. 14:2132014. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Rahman AA, Ngah WZ, Jamal R, Makpol S,
Harun R and Mokhtar N: Inhibitory mechanism of combined
hydroxychavicol with epigallocatechin-3-gallate against glioma
cancer cell lines: A transcriptomic analysis. Front Pharmacol.
13:8441992022. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Center MM and Jemal A: International
trends in liver cancer incidence rates. Cancer Epidemiol Biomarkers
Prev. 20:2362–2368. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Anwanwan D, Singh SK, Singh S, Saikam V
and Singh R: Challenges in liver cancer and possible treatment
approaches. Biochim Biophys Acta Rev Cancer. 1873:1883142020.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Chen CL, Chi CW and Liu TY: Enhanced
hydroxychavicol-induced cytotoxic effects in glutathione-depleted
HepG2 cells. Cancer Lett. 155:29–35. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Harsha C, Banik K, Ang HL, Girisa S,
Vikkurthi R, Parama D, Rana V, Shabnam B, Khatoon E, Kumar AP and
Kunnumakkara AB: Targeting AKT/mTOR in oral cancer: Mechanisms and
advances in clinical trials. Int J Mol Sci. 21:32852020. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Sawhney M, Rohatgi N, Kaur J, Shishodia S,
Sethi G, Gupta SD, Deo SVS, Shukla NK, Aggarwal BB and Ralhan R:
Expression of NF- kappaB parallels COX-2 expression in oral
precancer and cancer: Association with smokeless tobacco. Int J
Cancer. 120:2545–2556. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Baek SH, Ko JH, Lee H, Jung J, Kong M, Lee
JW, Lee J, Chinnathambi A, Zayed ME, Alharbi SA, et al:
Phytomedicine Resveratrol inhibits STAT3 signaling pathway through
the induction of SOCS-1: Role in apoptosis induction and
radiosensitization in head and neck tumor cells. Phytomedicine.
23:566–577. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Sinha N, Panda PK, Naik PP, Das DN,
Mukhopadhyay S, Maiti TK, Shanmugam MK, Chinnathambi A, Zayed ME,
Alharbi SA, et al: Abrus agglutinin promotes irreparable DNA damage
by triggering ROS generation followed by ATM-p73 mediated apoptosis
in oral squamous cell carcinoma. Mol Carcinog. 56:2400–2413. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Monisha J, Roy NK, Padmavathi G, Banik K,
Bordoloi D, Khwairakpam AD, Arfuso F, Chinnathambi A, Alahmadi TA,
Alharbi SA, et al: NGAL is downregulated in oral squamous cell
carcinoma and leads to increased survival, proliferation, migration
and chemoresistance. Cancers (Basel). 10:2282018. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Hashim D, Genden E, Posner M, Hashibe M
and Boffetta P: Head and neck cancer prevention : From primary
prevention to impact of clinicians on reducing burden. Ann Oncol.
30:744–756. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Behera AK, Kumar M, Shanmugam MK,
Bhattacharya A, Rao VJ, Bhat A, Vasudevan M, Gopinath KS,
Mohiyuddin A, Chatterjee A, et al: Functional interplay between YY1
and CARM1 promotes oral carcinogenesis. Oncotarget. 10:3709–3724.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Chang MC, Pan YH, Wu HL, Lu YJ, Liao WC,
Yeh CY, Lee JJ and Jeng JH: Stimulation of MMP-9 of oral epithelial
cells by areca nut extract is related to TGF-ß/Smad2-dependent
and-independent pathways and prevented by betel leaf extract,
hydroxychavicol and melatonin. Aging. 11:11624–11639. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Jeng JH, Wang YJ, Chang WH, Wu HL, Li CH,
Uang BJ, Kang JJ, Lee JJ, Hahn LJ, Lin BR and Chang MC: Reactive
oxygen species are crucial for hydroxychavicol toxicity toward KB
epithelial cells. Cell Mol Life Sci. 61:83–96. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Garbe C and Leiter U: Melanoma
epidemiology and trends. Clin Dermatol. 27:3–9. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Lomas A, Leonardi-Bee J and Bath-Hextall
F: A systematic review of worldwide incidence of nonmelanoma skin
cancer. Br J Dermatol. 166:1069–1080. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Green A, Whiteman D, Frost C and
Battistutta D: Sun exposure, skin cancers and related skin
conditions. J Epidemiol. 9:S7–S13. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
American Cancer Society, . Cancer Facts
& Figures 2016. American Cancer Society; Atlanta, GA: 2016
|
|
92
|
Moushumi L and Sumati B: Studies on
possible protective effect of plant derived phenols and the vitamin
precursors-β-carotene and α-tocopherol on 7, 12 Dimethylbenz (a)
anthracene induced tumour initiation events. Phytotherapy Res.
8:237–240. 1994. View Article : Google Scholar
|
|
93
|
Vinusri S, Gnanam R, Caroline R,
Santhanakrishnan VP and Kandavelmani A: Anticancer potential of
hydroxychavicol derived from piper betle L: An in silico and
cytotoxicity study. Nutr Cancer. 74:3701–3713. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Maeda H and Akaike T: Nitric oxide and
oxygen radicals in infection, inflammation, and cancer.
Biochemistry (Mosc). 63:854–865. 1998.PubMed/NCBI
|
|
95
|
Kennedy BM and Harris RE: Cyclooxygenase
and lipoxygenase gene expression in the inflammogenesis of breast
cancer. Inflammopharmacology. 26:909–923. 2018. View Article : Google Scholar
|
|
96
|
Romano M and Clària J: Cyclooxygenase-2
and 5-lipoxygenase converging functions on cell proliferation and
tumor angiogenesis: implications for cancer therapy. FASEB J.
17:1986–1995. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Schneider C and Pozzi A: Cyclooxygenases
and lipoxygenases in cancer. Cancer Metastasis Rev. 30:277–294.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Lin CF, Hwang TL, Chien CC, Tu HY and Lay
HL: A new hydroxychavicol dimer from the roots of Piper betle.
Molecules. 18:2563–2570. 2013. View Article : Google Scholar : PubMed/NCBI
|
